Program
lirafugratinib
Also written as “Lirafugratinib” and “RLY-4008”.
Its studies are mostly in Cholangiocarcinoma, led by Elevar Therapeutics.
Furthest: phase 2, since Aug 7, 20202 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Elevar Therapeutics | 21 open or running | phase 2since Aug 7, 2020 | Aug 7, 2020 | Sep 2027phase 2 · NCT07359820 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2020First study: phase 2 study in CholangiocarcinomaFirst studyNCT04526106 · 490 enrolled · United States, Australia, France and more
- Jan 16, 2026Phase 2 study in FGFR2 Gene Fusion/RearrangementNCT07359820 · 30 planned · United States, France, South Korea and more
Ahead
- Sep 2027Primary completion: phase 2 study in FGFR2 Gene Fusion/RearrangementNCT07359820
TargetBeta
FGFR2 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), ”NCIt, by rule
Other programs on FGFR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| FGFR2/3 Inhibitor CGT4859rule | cogent-biosciences-inc | phase 2 | 1 |
| KNT-0916rule | kinoteck-therapeutics-co-ltd | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07359820FGFR2 Gene Fusion/Rearrangement · United States, France, South Korea and more | 2 | Recruiting | Sep 2027 | 30 |
| NCT04526106Cholangiocarcinoma · United States, Australia, France and more | 2 | Completed | Sep 5, 2025 | 490 |
How it is read
Names in the registry
- “Lirafugratinib”, 1 entry
- “RLY-4008”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.